Literature DB >> 7564222

Tyrosinaemia type I: considerations of treatment strategy and experiences with risk assessment, diet and transplantation.

F J van Spronsen1, G P Smit, F A Wijburg, Y Thomasse, G Visser, H S Heymans.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7564222     DOI： 10.1007/BF00711742

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN： 0141-8955            Impact factor:   4.982


× No keyword cloud information.
  13 in total

1.  Liver transplantation for hereditary tyrosinemia--early transplantation following the patient's stabilization.

Authors:  E M Sokal; R Bustos; F Van Hoof; J B Otte
Journal:  Transplantation       Date:  1992-11       Impact factor: 4.939

2.  Liver transplantation for hereditary tyrosinemia in the presence of hepatocellular carcinoma.

Authors:  C O Esquivel; L Mieles; I R Marino; S Todo; L Makowka; G Ambrosino; P Nakazato; T E Starzl
Journal:  Transplant Proc       Date:  1989-02       Impact factor: 1.066

3.  Liver transplantation in tyrosinaemia type I: the Groningen experience.

Authors:  F A Wijburg; W C Reitsma; M J Slooff; F J van Spronsen; H A Koetse; D J Reijngoud; G P Smit; R Berger; C M Bijleveld
Journal:  J Inherit Metab Dis       Date:  1995       Impact factor: 4.982

4.  The occurrence of hepatoma in the chronic form of hereditary tyrosinemia.

Authors:  A G Weinberg; C E Mize; H G Worthen
Journal:  J Pediatr       Date:  1976-03       Impact factor: 4.406

5.  Hereditary tyrosinemia type I (chronic form): pathologic findings in the liver.

Authors:  L P Dehner; D C Snover; H L Sharp; N Ascher; R Nakhleh; D L Day
Journal:  Hum Pathol       Date:  1989-02       Impact factor: 3.466

6.  Neurologic crises in hereditary tyrosinemia.

Authors:  G Mitchell; J Larochelle; M Lambert; J Michaud; A Grenier; H Ogier; M Gauthier; J Lacroix; M Vanasse; A Larbrisseau
Journal:  N Engl J Med       Date:  1990-02-15       Impact factor: 91.245

7.  Liver transplantation for tyrosinemia. A review of 10 cases from the University of Pittsburgh.

Authors:  L A Mieles; C O Esquivel; D H Van Thiel; B Koneru; L Makowka; A G Tzakis; T E Starzl
Journal:  Dig Dis Sci       Date:  1990-01       Impact factor: 3.199

8.  Pediatric liver transplantation.

Authors:  T E Starzl; C Esquivel; R Gordon; S Todo
Journal:  Transplant Proc       Date:  1987-08       Impact factor: 1.066

9.  The effects of early treatment of hereditary tyrosinemia type I in infancy by orthotopic liver transplantation.

Authors:  M W Flye; C A Riely; B E Hainline; S Sassa; R J Gusberg; K J Blakemore; K W Barwick; A L Horwich
Journal:  Transplantation       Date:  1990-05       Impact factor: 4.939

10.  Early liver transplantation is indicated for tyrosinemia type I.

Authors:  D K Freese; M Tuchman; S J Schwarzenberg; H L Sharp; J M Rank; J R Bloomer; N L Ascher; W D Payne
Journal:  J Pediatr Gastroenterol Nutr       Date:  1991-07       Impact factor: 2.839
View more
  9 in total

1.  Neurocognitive outcome in patients with hypertyrosinemia type I after long-term treatment with NTBC.

Authors:  Eva Thimm; Renate Richter-Werkle; Gudrun Kamp; Bettina Molke; Diran Herebian; Dirk Klee; Ertan Mayatepek; Ute Spiekerkoetter
Journal:  J Inherit Metab Dis       Date:  2011-11-09       Impact factor: 4.982

2.  Renal function in tyrosinaemia type I after liver transplantation: a long-term follow-up.

Authors:  L J W M Pierik; F J van Spronsen; C M A Bijleveld; C M L van Dael
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

3.  Mutation spectrum of fumarylacetoacetase gene and clinical aspects of tyrosinemia type I disease.

Authors:  A Dursun; R K Ozgül; S Sivri; A Tokatlı; A Güzel; L Mesci; M Kılıç; D Aliefendioglu; F Ozçay; M Gündüz; T Coşkun
Journal:  JIMD Rep       Date:  2011-06-22

4.  Screening for tyrosinaemia type I.

Authors:  A C Hutchesson; S K Hall; M A Preece; A Green
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1996-05       Impact factor: 5.747

5.  Nitisinone in the treatment of hereditary tyrosinaemia type 1.

Authors:  Patrick J McKiernan
Journal:  Drugs       Date:  2006       Impact factor: 9.546

6.  Therapeutic trials in the murine model of hereditary tyrosinaemia type I: a progress report.

Authors:  M Grompe; K Overturf; M al-Dhalimy; M Finegold
Journal:  J Inherit Metab Dis       Date:  1998-08       Impact factor: 4.982

7.  NTBC treatment in tyrosinaemia type I: long-term outcome in French patients.

Authors:  A Masurel-Paulet; J Poggi-Bach; M-O Rolland; O Bernard; N Guffon; D Dobbelaere; J Sarles; H Ogier de Baulny; G Touati
Journal:  J Inherit Metab Dis       Date:  2008-01-25       Impact factor: 4.982

Review 8.  Single amino acid supplementation in aminoacidopathies: a systematic review.

Authors:  Danique van Vliet; Terry G J Derks; Margreet van Rijn; Martijn J de Groot; Anita MacDonald; M Rebecca Heiner-Fokkema; Francjan J van Spronsen
Journal:  Orphanet J Rare Dis       Date:  2014-01-13       Impact factor: 4.123

9.  Experience of a Single Center in NTBC Use in Management of Hereditary Tyrosinemia Type I in Libya.

Authors:  Hanna Alobaidy; Emna Barkaoui
Journal:  Iran J Pediatr       Date:  2015-10-06       Impact factor: 0.364
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.